

Doncaster & Bassetlaw Medicines Formulary

Section 6.1.1: Insulins

Short Acting Insulins

Actrapid

Novorapid

Humalog (including Humalog 200units/ml Kwikpen)

FIASP

Intermediate and Long Acting Insulins

Humulin I

Semglee

Toujeo (available as 300units/ml Solostar)

Levemir

Humulin M3

Novomix 30

Humalog Mix 25

Humalog Mix 50

Approved by Drug and Therapeutics Committee: January 2022

Review Date: January 2025

Prescribing Guidance:

Guidance below should be read in conjunction with NICE guidance via:

<http://www.nice.org.uk/guidance/ng17>

Given the availability of biosimilars and different strengths of a variety of insulin preparations, the MHRA have released guidance around the prescribing of insulin preparations:

<https://www.gov.uk/drug-safety-update/high-strength-fixed-combination-and-biosimilar-insulin-products-minimising-the-risk-of-medication-error>

KEY: ^[UL] Unlicensed Preparation; **Drug** – first line choice; **Drug** – hospital only; **Drug** – Amber (TLS), **Drug** – Red (TLS), see <http://medicinesmanagement.doncasterccg.nhs.uk/traffic-light-system/>

Items for Restricted Prescribing:

Insulin Degludec may be of use in a small subgroup of patients who fail to maintain glycaemic control overnight and in whom nocturnal hypoglycaemia is an issue despite optimisation of medication regimen or those with an unpredictable lifestyle, e.g. shift workers.

Given the cost of this insulin it should be reserved for those patients who have previously tried other cheaper insulin analogues.

NICE guidance relating to this insulin can be found here.

[Type 1 Diabetes](#)

[Type 2 Diabetes](#)

Insulin Degludec/Liraglutide (Xultophy) is available for diabetic specialist use where the combination of a GLP-1 receptor agonists and insulin are indicated.